The Patent Finder
ID

International - Drug - Development - Biotech

First filing 2013
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Four patents currently held, every record listed here

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jul 2031. from the record

Of the 1 now held by other companies, 1 name Genmab B.V. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jul 2031
Next term end
4
Patent families

When these terms end

Each bar runs from grant to computed term end. 2015 to 2041.
US 9,120,856 ANTI-CD19 Antibody Having Adcc Function with Improved Glycosylation Profile Jul 18, 2031
US 9,611,327 ANTI-DR5 Family Antibodies, Bispecific or Multivalent ANTI-DR5 Family Antibodies and Methods of Use Thereof Oct 31, 2033
US 10,533,046 ANTI-CK8 Antibodies for Use in the Treatment of Colorectal Cancers Oct 6, 2035
US 11,634,488 Treatment of B Cell Malignancies Using Afucosylated Pro-Apoptotic ANTI-CD19 Antibodies in Combination with Anti CD20 Antibodies or Chemotherapeutics Mar 10, 2039
US 12,077,597 ANTI-CD5 Antibodies and Methods of Use Thereof Nov 24, 2041
202020252030203520402041
Every computed term in this portfolio is shown above.Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 1, 2027
    The maintenance fee for ANTI-CD19 Antibody Having Adcc Function with Improved Glycosylation Profile (US 9,120,856) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
  • 1 fee due Jul 14, 2027
    The maintenance fee for ANTI-CK8 Antibodies for Use in the Treatment of Colorectal Cancers (US 10,533,046) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

The 3 largest of its 4 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 4 of 4

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,120,856ANTI-CD19 Antibody Having Adcc Function with Improved Glycosylation Profile
In force
 · High confidence
In forceHigh confidence
US 10,533,046ANTI-CK8 Antibodies for Use in the Treatment of Colorectal Cancers
In force
 · High confidence
In forceHigh confidence
US 11,634,488Treatment of B Cell Malignancies Using Afucosylated Pro-Apoptotic ANTI-CD19 Antibodies in Combination with Anti CD20 Antibodies or Chemotherapeutics
In force
 · High confidence
In forceHigh confidence
US 12,077,597ANTI-CD5 Antibodies and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 4: 1 patent in force now held by others · 2 patents ended · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited